Global Roundup: EU Approves ViiV’s HIV-1 Drug and More
The Pharma Data
DECEMBER 23, 2020
based Avacta Group entered into a license agreement with Astrea Bioseparations that allows that company to use Avacta’s Affimer platform in affinity purification applications. The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation.
52 
Let's personalize your content